Book a demo

Cut patent&paper research from weeks to hours with PatSnap Eureka AI!

Try now
Merck & Pfizer v. Zenara Pharma: Consent Judgment Patent Case | PatSnap
Patent Litigation

Merck & Pfizer v. Zenara Pharma — Consent Judgment After 421 Days

Merck Sharp & Dohme, Pfizer, and affiliated MSD entities brought a patent infringement action against Zenara Pharma in Delaware District Court, asserting US Patent No. 8,080,580 covering dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives. The case resolved via court-entered consent judgment, with Zenara enjoined from infringing the Licensed Patent absent authorization under the parties' Settlement Agreement.

Resolution time
421days
421 days from filing to consent judgment — typical for ANDA patent consent resolutions in Delaware
Patents asserted
1
US8080580B2 — dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives, pharmaceutical compound patent
Outcome
Consent Judgment
Agreed by the parties, entered by the Delaware District Court — binding, final, with injunction retained
Cost ruling
No Costs Awarded
Dismissed with prejudice and without costs, disbursements, or attorneys' fees to any party
Published by PatSnap Insights Team · Verified by PatSnap Eureka Data
Case overview

Pharma patent dispute resolved by consent judgment and injunction

On 23 March 2022, Merck Sharp & Dohme LLC, Pfizer Inc., MSD International Business GmbH, MSD International GmbH, and PF PRISM IMB C.V. (collectively referred to in the proceedings as 'Merck') filed a patent infringement action in the Delaware District Court against Zenara Pharma Private Limited. The suit centred on US Patent No. 8,080,580, which covers dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives, and was triggered by Zenara's Abbreviated New Drug Application No. 216842 seeking to market a generic version of the relevant drug product.

The case closed on 18 May 2023 via a court-entered consent judgment. Under the judgment, Zenara and its affiliates, successors, and assigns are enjoined from infringing US8080580 by making, using, selling, offering to sell, importing, or distributing the Zenara Product unless specifically authorised pursuant to the parties' Settlement Agreement. All claims, counterclaims, affirmative defenses, and demands were dismissed with prejudice and without costs to any party. The Delaware District Court expressly retained jurisdiction to enforce or supervise performance under both the Consent Judgment and the Settlement Agreement.

The case resolved in approximately 14 months — without proceeding to trial — consistent with negotiated resolution patterns seen in ANDA-related Hatch-Waxman proceedings. The specific commercial terms governing any authorised entry of the Zenara Product are set out in the Settlement Agreement referenced in the Consent Judgment; those terms are not disclosed in the available public record.

See Complete Case & Patent Analysis →
Case at a glance
CourtDelaware District Court
JudgeGregory B. Williams
FiledMarch 23, 2022
ClosedMay 18, 2023
Duration421 days
OutcomeConsent Judgment
Verdict causeInfringement Action
BasisConsent Judgment
Prior Art Intelligence
See what prior art exists on this patent.
Eureka scans millions of patents and papers to surface prior art that may have invalidated these claims before costly litigation begins.
Check Prior Art
Case data sourced from PACER / Delaware District Court via PatSnap Eureka Litigation Intelligence Explore similar cases ↗
Case timeline

Filing to Consent Judgment in 421 days

421 days from filing to consent judgment — typical for ANDA patent consent resolutions in Delaware

Case timeline: Complaint filed MAR 23 2022 — 421 days total Horizontal timeline showing the three key events in Merck Sharp & Dohme, LLC v Zenara Pharma Private, Ltd. from filing to resolution. Source: PACER, Delaware District Court. MAR 23 2022 Complaint filed Pre-trial proceedings MAY 18 2023 Consent Judgment 421 DAYS TOTAL
Patent at issue

US8080580B2 — Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Publication No.US8080580B2
Application No.US12/546306
Patent details
ProductDioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives — pharmaceutical compound
Cited in actionMarch 23, 2022
Technical brief · sourced from PatSnap patent database
US8080580B2Primary patent
Patent figurePatent figure
Technology summary
Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives, specifically compounds of Formulas (A) and (B), serve as effective SGLT2 inhibitors, addressing the need for safer treatments for obesity and Type 2 diabetes by enhancing glucose excretion and reducing blood glucose levels, offering a safer alternative to existing genotoxic glycosides.
Representative claim (1 of 9 independent)
1. A compound of Formula (A) or Formula (B) wherein R 1 is H, (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, Cl, F, cyano, fluoro-substituted (C 1 -C 2 )alkyl, (C 1 -C 4 )alkyl-SO 2 —, or (C 3 -C 6 )cycloalkyl; and R 2 is (C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, (C 2 -C 4 )alkynyl, 3-oxetanyloxy, 3-tetrahydrofuranyloxy, Cl, F, cyano, fluoro-substituted (C 1 -C 2 )alkyl, (C 1 -C 4 )alkyl-SO 2 —, (C 3 -C 6 )cycloalkyl, or a (C 5 -C 6 )heterocycle having 1 or 2 heteroatoms each independently selected from N, O, or S.
Technical background
RELATED APPLICATIONS This application claims the benefit of priority under 35 U.S.C. 119(e) of U.S. Provisional Application Ser. Nos. 61/092,470, filed Aug. 28, 2008, and 61/227,212, filed Jul. 21, 2009, both of which are incorporated herein by reference in their entireties for all purposes. FIELD OF THE INVENTION The present invention relates to dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives, crystal structures, pharmaceutical compositions and the uses thereof as sodium-glucose co-transporter (SGLT) inhibitors…
Patent family
106 family members across 58 jurisdictions (HU, PH, MN, GE, RS, KR, ES, EP, EC, SI, CN, ID)
PatSnap Eureka · FTO Search Agent
Should you run an FTO analysis against US8080580B2?

Any pharmaceutical developer, generic manufacturer, or ANDA applicant working with dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives or structurally adjacent compounds should treat US8080580 as a live blocking patent. The Delaware consent judgment confirms that Merck and Pfizer will pursue injunctive relief — and the court's retained jurisdiction means enforcement is immediate, not subject to a fresh infringement filing. FTO analysis is essential before committing to a product development or regulatory filing strategy.

Run FTO in Eureka
Patent data sourced from USPTO via PatSnap Eureka patent database Search patent records in Eureka ↗
Official verdict

Official order — verbatim text

Merck Sharp & Doh.me LLC, MSD International Business GmbH, MSD International GmbH, Pfizer Inc., and PF PRISM IMB B.V. (collectively "Merck"), and Zenara Pharma Private Limited ("Zenara"), the parties in the above-captioned action, have agreed to terms and conditions representing a negotiated settlement of the action and have set forth those terms and conditions in a Settlement Agreement (the "Settlement Agreement"). Now the parties, by their respective undersigned attorneys, hereby stipulate and consent to entry of judgment and an injunction in the action, as follows: 1. This District Court has jurisdiction over the subject matter of the above actions and has personal jurisdiction over the parties. 2. As used in this Consent Judgment, (i) the term "Zenara Product" shall mean the drug product sold, offered for sale or distributed pursuant to Abbreviated New Drug Application No. 216842 (and defined in greater detail in the Settlement Agreement); (ii) the term "Licensed Patent" shall mean United States Patent Number 8,080,580; and (iii) the term "Affiliate" shall mean any entity or person that, directly or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with Zenara; for purposes of this definition, "control" means (a) ownership, directly or through one or more intermediaries, of (1) more than fifty percent (50%) of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or (2) more than fifty percent (50%) of the equity interests in the case of any other type of legal entity or status as a general partner in any partnership, or (b) any other arrangement whereby an entity or person has the right to elect a majority of the Board of Directors or equivalent governing body of a corporation or other entity or the right to direct the management and policies of a corporation or other entity. 3. Unless otherwise specifically authorized pursuant to the Settlement Agreement, Zenara, including any of its Affiliates, successors and assigns, is enjoined from infringing the Licensed Patent, on its own part or through any Affiliate , by making, having made, using, selling, offering to sell, importing or distributing of the Zenara Product. 4. Compliance with this Consent Judgment may be enforced by Merck and its successors in interest, or assigns, as permitted by the terms of the Settlement Agreement. 5. This District Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and the Settlement Agreement.6. All claims, counterclaims, affirmative defenses and demands in this action are hereby dismissed with prejudice and without costs, disbursements or attorneys' fees to any party. We hereby consent to the form and entry of this Order:
Source: PACER Docket, Case 1:22-cv-00379, Delaware District Court

The consent judgment order sets out an agreed injunction and dismissal with prejudice, entered by the Delaware District Court on the parties' joint stipulation. The court's express retention of jurisdiction to enforce or supervise performance under both the Consent Judgment and the referenced Settlement Agreement means the order functions as an ongoing compliance instrument, not merely a case-closing formality.

PACER case 1:22-cv-00379 · Public docket record Explore in Eureka ↗
Judgment terms

Consent judgment: what the agreed resolution means for both parties

Legal mechanism

A consent judgment is a binding, court-entered order on agreed terms

A consent judgment reflects terms negotiated by the parties and then formally entered by the court, giving those terms the force of a judicial order. Here, the Delaware District Court entered the judgment on the parties' joint stipulation, including an injunction against Zenara. The court expressly retained jurisdiction to enforce or supervise performance — meaning non-compliance can be addressed through contempt or other court process, not merely contract litigation.

Court-entered, binding and final
Patent holder outcome

Merck and Pfizer secure an enforceable injunction protecting US8080580

The consent judgment delivers Merck and Pfizer a court-order barring Zenara — including affiliates, successors, and assigns — from infringing US8080580 through any act of making, using, selling, offering for sale, importing, or distributing the Zenara Product, unless authorised under the Settlement Agreement. Enforcement rights are expressly preserved for Merck and its successors or assigns. The patent's commercial protection is thus court-backed, not merely contractual.

Injunction secured, patent enforced
Defendant outcome

Zenara enjoined unless authorised by Settlement Agreement

Zenara Pharma is restrained from commercialising its ANDA No. 216842 product in ways that would infringe US8080580, absent specific authorisation under the Settlement Agreement. The dismissal is with prejudice, foreclosing re-litigation of the same claims. The specific terms of any authorised market entry — including timing or volume conditions — are set out in the Settlement Agreement and are not disclosed in the available public record.

Dismissed with prejudice, no costs
Commercial implications

Court-retained jurisdiction raises enforcement stakes for future generic filers

The court's express retention of jurisdiction to supervise performance signals that the consent judgment is more than a paper settlement — it is an active compliance framework. For other ANDA applicants or generic developers in the dioxa-bicyclo derivative space, this outcome signals that Merck and Pfizer are willing to litigate and obtain injunctive relief. Any generic entrant referencing the same compound class should assess US8080580's claim scope carefully before committing to a commercialisation strategy.

Injunction enforceable, court oversight retained
Legal analysis based on PACER docket records for case 1:22-cv-00379 and PatSnap Eureka litigation intelligence Search PatSnap Eureka ↗
Parties and representation

Full party and counsel information

RoleNameTypeDetail
PlaintiffMerck Sharp & Dohme, LLCCompany/Search in Eureka ↗
Co-PlaintiffPfizer, Inc.CompanySearch in Eureka ↗
Co-PlaintiffMSD International Business, GmbHCompanySearch in Eureka ↗
Co-PlaintiffMSD International, GmbHCompanySearch in Eureka ↗
Co-PlaintiffPF Prism Ibm C.V.IndividualSearch in Eureka ↗
DefendantZenara Pharma Private, Ltd.Company/Search in Eureka ↗
Plaintiff counselJack B. BlumenfeldAttorneyCounsel for Merck Sharp & Dohme, LLCSearch in Eureka ↗
Plaintiff counselMegan Elizabeth DellingerAttorneyCounsel for Merck Sharp & Dohme, LLCSearch in Eureka ↗
Plaintiff law firmMorris, Nichols, Arsht & Tunnell LLPLaw FirmRepresenting Merck Sharp & Dohme, LLCSearch in Eureka ↗
Defendant counselDmitry V. ShelhoffAttorneyCounsel for Zenara Pharma Private, Ltd.Search in Eureka ↗
Defendant counselEdward D. PergamentAttorneyCounsel for Zenara Pharma Private, Ltd.Search in Eureka ↗
Defendant counselEve H. OrmerodAttorneyCounsel for Zenara Pharma Private, Ltd.Search in Eureka ↗
Defendant counselJulia S. KimAttorneyCounsel for Zenara Pharma Private, Ltd.Search in Eureka ↗
Defendant counselKenneth S. CanfieldAttorneyCounsel for Zenara Pharma Private, Ltd.Search in Eureka ↗
Defendant counselNeal C. BelgamAttorneyCounsel for Zenara Pharma Private, Ltd.Search in Eureka ↗
Defendant law firmSmith, Katzenstein, & Jenkins LLPLaw FirmRepresenting Zenara Pharma Private, Ltd.Search in Eureka ↗
Presiding judgeJudge Gregory B. WilliamsJudgeDelaware District CourtSearch in Eureka ↗
R&D signals

R&D signals in the dioxa-bicyclo pharmaceutical compound space

Forward-looking patent and R&D intelligence for teams operating in the dioxa-bicyclo[3.2.1]octane derivative and SGLT-related pharmaceutical compound landscape, drawn from this Merck-Pfizer v. Zenara dispute.

Patent portfolio

Merck and Pfizer's compound patent filings in the dioxa-bicyclo derivative space

US8080580 is jointly enforced by a multi-entity Merck-Pfizer structure, suggesting a co-ownership or co-licensing arrangement across the underlying compound family. R&D teams should map the full Merck Sharp & Dohme and Pfizer portfolio around dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives to identify continuation, divisional, or related compound patents that may extend blocking coverage beyond this single patent.

Merck-Pfizer compound portfolio
Technology landscape

Filing trends in bicyclic sugar derivative pharmaceutical compounds

Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives represent a structurally specific class within broader bicyclic sugar-based pharmaceutical chemistry, a space associated with metabolic disease candidates. Monitoring patent filing activity and IPC classification trends in this compound class can surface competitive R&D programmes before they reach clinical or regulatory stages — a key early-warning signal for both innovators and generic developers.

Bicyclic compound filing trends
Competitor IP posture

Zenara Pharma's ANDA pipeline and patent challenge activity

Zenara Pharma's filing of ANDA No. 216842 signals an active interest in generic entry for this compound class. Tracking Zenara's broader ANDA pipeline and any Paragraph IV certification activity can provide early intelligence on which other patented compounds the company is targeting — relevant for branded holders and competing generic developers seeking to anticipate market entry timelines.

Generic entry pipeline intelligence
White space opportunity

Adjacent compound structures outside US8080580's claim scope

US8080580 covers a specific dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivative structure. Structural analogues, alternative stereochemistry, or modified ring systems in adjacent chemical space may fall outside the patent's claim boundaries — representing potential white-space for novel compound development. A freedom-to-operate and landscape analysis of the surrounding chemical space can identify design-around opportunities or unencumbered filing positions.

Design-around compound space
Related litigation

Similar ANDA patent infringement cases in Delaware District Court

Explore comparable Hatch-Waxman pharmaceutical patent infringement cases in the Delaware District Court involving consent judgments and ANDA-triggered injunctions.

🔍
Access 40+ similar cases in PatSnap Eureka
Merck Sharp & Dohme, LLC patent enforcement history, Delaware District Court case history, Merck Sharp & Dohme, LLC's full IP portfolio, and comparable case analysis
Related ANDA casesMerck patent disputesPfizer infringement suitsDelaware pharma consent judgments
Unlock similar cases in Eureka →
Strategic implications

What this case signals for the pharmaceutical patent IP landscape

A consent judgment with injunction in a Hatch-Waxman ANDA case carries specific strategic weight for generic developers and branded pharma patent holders alike.

Consent judgments with retained jurisdiction create ongoing compliance risk for generic filers

The Delaware District Court's express retention of jurisdiction means Zenara's compliance can be tested in court without fresh litigation. For in-house IP teams at generic companies, this underscores the need to monitor Settlement Agreement terms closely — any deviation from authorised activity could trigger contempt proceedings, not just a new infringement suit.

US8080580 remains active and court-backed — FTO analysis is essential for ANDA applicants

With US8080580 now protected by a court-entered injunction and expressly listed as the 'Licensed Patent' in the consent judgment, any ANDA applicant covering dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives must treat this patent as a live blocking risk. A freedom-to-operate analysis against this patent — and Merck and Pfizer's broader portfolio — is a prerequisite before filing.

🔒
Full strategic analysis in PatSnap Eureka
Unlock full strategic analysis of this Delaware District Court pharmaceutical patent consent judgment, including portfolio and enforcement intelligence.
Patent ownership chainGeneric entry timing signalsMerck-Pfizer enforcement history
Unlock full analysis →
Analysis powered by PatSnap Eureka Litigation Intelligence Explore in Eureka ↗
Frequently asked questions

Merck v Zenara — key questions answered

Still have questions? PatSnap Eureka can answer them instantly from patent and litigation data. Ask Eureka ↗
PatSnap Eureka

Monitor pharmaceutical patent enforcement and ANDA risks with PatSnap

US8080580 is now court-backed with a retained-jurisdiction injunction. Use PatSnap Eureka to run freedom-to-operate analysis, track Merck and Pfizer's compound patent portfolio, and receive alerts on related ANDA litigation in Delaware and beyond.

Disclaimer

This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.

Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.

Ask anything about this case.
PatSnap Eureka searches patents and litigation data to answer instantly.
Powered by PatSnap Eureka
Link copied to clipboard

Related Litigation Cases

Help us improve this page

Found incorrect or outdated information? Let us know and we'll get it fixed.